Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.67 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.67 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | TNKS | O95271 | 6/20 | 0.62 |
| ▸ | PARP1 | P09874 | 3/20 | 0.62 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9284336 | 0.86 | HPGD (0.70) | HPGDNPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL15676317 | 0.86 | HPGD (0.74) | HPGDNPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL7583434 | 0.83 | HPGD (0.70) | HPGDNPC1RAB9ASMN1; SMN2AKR1C3 | |
| Flavone SCHEMBL27686205 | 0.82 | TNKS (0.84) | HPGDNPC1RAB9ASMN1; SMN2TNKS | |
| SCHEMBL4634256 | 0.81 | HPGD (0.73) | HPGDNPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL11035644 | 0.81 | HPGD (0.63) | HPGDNPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL25186939 | 0.80 | HPGD (0.67) | HPGDNPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL2436664 | 0.80 | HPGD (0.67) | HPGDNPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL8025501 | 0.80 | HPGD (0.67) | HPGDNPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL530293 | 0.80 | HPGD (0.67) | HPGDNPC1RAB9ASMN1; SMN2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119470756-A | UPLC quantitative fingerprint detection method for camphor head red tangerine peel | 赣江中药创新中心 | 2025-02-18 | — | — | CN | claimed |
| CN-112294794-B | Application of methyl ophiopogonone A in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease and liver injury | 四川大学 | 2021-07-30 | — | — | CN | claimed |
| CN-112294794-A | Application of methyl ophiopogonone A in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease and liver injury | 四川大学 | 2021-02-02 | — | — | CN | claimed |
| US-5399584-A | Preventing gastrointestinal damage caused by nonsteroidal antiinflammatory drugs | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-21 | — | — | US | claimed |
| US-20250263774-A1 | DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD | UNIV NORTH TEXAS (US) | 2025-08-21 | — | — | US | disclosed |
| CN-112013989-B | Lower critical temperature indicating device | 江苏集萃智能液晶科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4511018-A1 | 4-CHROMONE DERIVATIVES AS N-POLYMERASE INHIBITORS FOR USE IN THE TREATMENT PLATINUM RESISTANT METASTATIC NEOPLASM | Fondazione Istituto Italiano di Tecnologia (IT) | 2025-02-26 | — | — | EP | disclosed |
| US-11844820-B2 | Topical formulation and uses thereof | ARTHRITIS RELIEF PLUS LTD. (AU) | 2023-12-19 | — | — | US | disclosed |
| WO-2023203535-A1 | 4-CHROMONE DERIVATIVES AS N-POLYMERASE INHIBITORS FOR USE IN THE TREATMENT PLATINUM RESISTANT METASTATIC NEOPLASM | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2023-10-26 | — | — | WO | disclosed |
| US-20220331431-A1 | COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS | MONELL CHEMICAL SENSES CENTRE (US) | 2022-10-20 | — | — | US | disclosed |
| CN-113956226-A | Method for synthesizing carvachin | 南京科技职业学院 | 2022-01-21 | — | — | CN | disclosed |
| US-11207265-B2 | Extract of the aerial parts of Lawsonia inermis and its preparation method | PIERRE FABRE DERMO-COSME FIQUE (FR) | 2021-12-28 | — | — | US | disclosed |
| US-20080214492-A1 | Folate based composition for treatment of the cardiovascular system | CONCOURSE HEALTH SCIENCES LLC | 2008-09-04 | — | — | US | disclosed |
| US-20070149466-A1 | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | SIRTRIS PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20060116334-A1 | Folate based composition for treatment of the cardiovascular system | CONCOURSE HEALTH SCIENCES LLC | 2006-06-01 | — | — | US | disclosed |
| US-5399584-A | Preventing gastrointestinal damage caused by nonsteroidal antiinflammatory drugs | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0100250-B1 | METHYLFLAVONE DERIVATIVES | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1987-03-04 | — | — | EP | disclosed |
| EP-0100250-B1 | METHYLFLAVONE DERIVATIVES | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1987-03-04 | — | — | EP | disclosed |
| US-4594345-A | Containing a 2-phenyl substituted chroman-4-one ring | NIPPON SHINYAKU CO. LTD. (JP) | 1986-06-10 | — | — | US | disclosed |
| EP-0100250-A2 | Methylflavone derivatives | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1984-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844820-B2 | Topical formulation and uses thereof | SYMPK, MMP13, MMP7 | HPGD 264/4885NPC1 808/4885RAB9A 2441/4885 |
| US-11207265-B2 | Extract of the aerial parts of Lawsonia inermis and its preparation method | KRT18, MKI67, CD68 | HPGD 2356/4885NPC1 4094/4885RAB9A 3662/4885 |
| US-20220331431-A1 | COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS | HTR6, FOS, API5 | HPGD 2156/4885NPC1 2111/4885RAB9A 618/4885 |
| US-20070149466-A1 | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | SIRT1, SIRT3, SIRT2 | HPGD 476/4885NPC1 516/4885RAB9A 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.